“This approval is based on comprehensive results from two Phase 3 studies, which were recently published in Blood.In these studies, which included 441 patients who had either never been treated with a complement inhibitor before, or who had been stable on SOLIRIS, the efficacy of ULTOMIRIS administered every eight weeks was non-inferior to the efficacy
- Welcome to PNH Support!
News
1st December 2018
CONCORD (CoOrdiNated Care Of Rare Disease) Research Project
Genetic Alliance UK still have spaces available in upcoming focus groups for their research project CONCORD (CoOrdiNated Care Of Rare Disease). They are currently recruiting for focus groups for rare disease patients, carers and healthcare professionals. These focus groups are crucial to help the researchers understand the needs and concerns of both patients and healthcare
1st October 2018
CO-ORDINATED CARE OF RARE DISEASES (CONCORD)
10th August 2018
Article on Treating AA and PNH at the same time.
12th July 2018
Results from Phase 1b Studies for C3 Inhibitor
12th July 2018
Phase 1 Trial starts for Achillion’s Oral Therapy
9th February 2018
